Articles

Highlights in digestive oncology

BJMO - volume 16, issue 5, september 2022

H. Oliveres MD, T. Vandamme MD, PhD, H. Prenen MD, PhD

SUMMARY

The 2022 ASCO Annual Meeting was held in Chicago, USA, between the 3rd and 7th of June 2022. The main goal of this overview is to highlight the most striking abstracts in the field of digestive oncology for daily clinical practice. First, the upper gastro-intestinal tract tumours will be discussed, followed by an overview of the congress highlights related to cancers of the lower gastro-intestinal tract.

(Belg J Med Oncol 2022;16(5):223–8)

Read more

Capecitabine and folic acid: A lethal combination?

BJMO - volume 16, issue 2, march 2022

D. Naudts MD, L-A. Teuwen MD, J. Van Boven , H. Prenen MD, PhD, T. Vandamme MD, PhD, B. Van Overberghe MD, K. Forceville MD, M. Peeters MD, PhD

SUMMARY

5-Fluorouracil (5-FU) and its prodrug capecitabine are widely used and generally well-tolerated chemotherapeutic agents. Although leucovorin, a derivative of folic acid, is routinely used to potentiate the effect of 5-FU, there seems to be little to no awareness about a similar interplay between capecitabine and folic acid, a commonly used supplement. This study presents a case in which a high concentration of folic acid led to fatal capecitabine-related toxicity, with the aim to raise awareness on the interaction between folic acid supplementation and 5-FU/capecitabine treatment toxicity.

(BELG J MED ONCOL 2022;16(2):74–8)

Read more

Highlights in digestive oncology

BJMO - volume 15, issue 8, december 2021

H. Dedecker MD, L-A. Teuwen MD, T. Vandamme MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD

The 2021 edition of ESMO was held virtually between the 16th and 21st of September 2021. The main goal of this overview is to highlight the most striking abstracts in the field of digestive oncology for daily clinical practice. First, the upper gastro-intestinal tract tumours will be discussed, followed by an overview of the congress highlights related to cancers of the lower gastro-intestinal tract.

(BELG J MED ONCOL 2021;15(5):415–20)

Read more

Highlights in digestive oncology

BJMO - volume 14, issue 8, december 2020

L-A. Teuwen MD, M. Peeters MD, PhD, T. Vandamme MD, PhD, H. Prenen MD, PhD

The annual ESMO meeting was held virtually between 19th and 21st September 2020 and covered many interesting abstracts in the field of digestive oncology. In this overview, our main aim was to highlight the data that are most relevant for daily clinical practice. This year, we will discuss the results according to the traditional division in upper and lower gastro-intestinal tract tumours.

Read more

Highlights of the European Neuroendocrine Tumour Society (ENETS) Congress

BJMO - volume 14, issue 6, october 2020

W. Lybaert MD, T. Vandamme MD, PhD, G. Boons , L. De Backer , M. Peeters MD, PhD, NETwerk Antwerpen-Waasland , ENETS Centre of Excellence

The 17th Annual European Neuroendocrine Tumour Society (ENETS) Congress took place as a virtual meeting from March 11th until March 13th, 2020. This article will provide you with the highlights discussed at the meeting.

Read more

Highlights in digestive oncology

BJMO - volume 14, issue 5, september 2020

H. Prenen MD, PhD, T. Vandamme MD, PhD, M. Peeters MD, PhD

Summary

At this years’ virtual annual ASCO meeting, a wide range of interesting studies in the field of gastrointestinal (GI) cancer were presented. The aim of this overview is to discuss the most important of these studies, with a particular focus on data that have the potential to be practice changing. For practical reasons, this report will not follow the traditional subdivision in cancers from the upper and lower GI tract, but will rather focus on three major therapeutic strategies: neoadjuvant therapy, immunotherapy and targeted therapy.

(BELG J MED ONCOL 2020;14(5):183-7)

Read more

Adjuvant chemotherapy of colon cancer: 3 versus 6 months

BJMO - volume 13, issue 6, october 2019

C. Debeuckelaere MD, L. Triest MD, T. Vandamme MD, PhD, B. Van den Heuvel MD, K. Papadimitriou MD, PhD, M. Rasschaert MD, H. Prenen MD, PhD, M. Peeters MD, PhD

Summary

For over a decade, oxaliplatin-based adjuvant chemotherapy has been the gold standard for resected early colon cancer. Oxaliplatin is known to cause polyneuropathy, which affects quality of life dramatically. In recent years, there has not been any progress in the development of novel agents to replace oxaliplatin as adjuvant therapy. Consequently, there is a growing interest to investigate whether a shorter course of chemotherapy is sufficient. This article will discuss the history of adjuvant treatment in early-resected colon cancer, the toxicity of oxaliplatin, the results from the IDEA meta-analysis and future prospects.

(BELG J MED ONCOL 2019;13(6):234–239)

Read more
X